Charming Medical, Limited – Investigated by Federman & Sherwood
January 15, 2026– The law firm of Federman & Sherwood, a nationally recognized plaintiffs’ litigation firm representing shareholders and investors in complex securities matters, today announced that it has commenced an independent investigation into potential securities law violations by Charming Medical, Limited (“Charming Medical” or the “Company”) on behalf of purchasers of the Company’s common stock.
Details of the Investigation:
Federman & Sherwood’s investigation focuses on whether Charming Medical and certain of its officers and directors may have made materially false or misleading statements, and/or failed to disclose material information to investors regarding the Company’s business, operations, and prospects.
According to allegations in a recently filed securities action, Charming Medical may have misrepresented the nature, scope and progress of its medical device development programs, including the status and commercialization prospects of its key products and technologies. The investigation also is evaluating whether the Company failed to disclose adverse regulatory developments, operational challenges, or financial conditions that may have impacted the Company’s performance and stock price.
As a result of these alleged misstatements and omissions, it is further alleged that Charming Medical’s public statements were materially false or misleading during the relevant period, and that investors may have suffered financial losses when the true state of the Company’s business was revealed.
Background:
Charming Medical, Limited is a company engaged in the research, development, manufacturing and marketing of medical devices. The Company’s common stock has been publicly traded, and Charming Medical has issued various public statements regarding its product development, regulatory pathway, business strategy, and expected future results. The investigation seeks to determine whether those statements complied with applicable securities laws and whether investors had timely and accurate information to reasonably assess the value and prospects of their investment.
What This Means for Investors:
Investors who purchased or otherwise acquired Charming Medical, Limited common stock during the relevant period and suffered financial losses may contact Federman & Sherwood for a free and confidential consultation. The firm is evaluating potential legal claims and all available remedies on behalf of affected shareholders.
CONTACT FEDERMAN & SHERWOOD
Attorney Sara Collier is widely regarded as a leading attorney in the field of derivative shareholder litigation. She is driven by a deep commitment to ensuring that boards of directors and corporate executives of publicly traded companies answer to the shareholders they serve.
With over ten years of experience pursuing derivative cases nationwide—particularly in Delaware, the home jurisdiction for many major corporations—Ms. Collier has developed a reputation for skillfully pushing even the largest companies toward stronger transparency and accountability in their corporate governance.
Phone: (405) 235-1560
Contact Form
Email : sec@federmanlaw.com